Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

BACKGROUND: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. OBJECTIVES: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in patients with chronic plaque psoriasis treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Rungapiromnan, W., Mason, K.J., Lunt, M., McElhone, K., Burden, A.D., Rutter, M.K., Warren, R.B., Griffiths, C.E.M., Ashcroft, D.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155017/
https://www.ncbi.nlm.nih.gov/pubmed/31633837
http://dx.doi.org/10.1111/jdv.16018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155017/
https://www.ncbi.nlm.nih.gov/pubmed/31633837
http://dx.doi.org/10.1111/jdv.16018

Ejemplares similares